The recent approval of PARP inhibitors for the treatment of metastatic castration-resistant
prostate cancer (mCRPC) patients with BRCA mutations firstly introduced the possibility of …

PARP inhibitors (PARPi) gained major interest among prostate cancer researchers in the
last few years, thanks to the outstanding results coming from the PROfound an TRITON2 …

PURPOSE Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib)
are US Food and Drug Administration–approved for patients with metastatic castration …

Management of castration-resistant prostate cancer (CRPC) is a major problem and lie
behind∼ 5% of adult male deaths in Northern European countries. Recently, Johann de …

The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

Despite the development of novel effective therapeutic strategies, metastatic castration-
resistant prostate cancer (mCRPC) remains a disease with a lethal course and a high …

Background: Recent advances in genetic sequencing and recent studies focusing on the
broader use of Poly ADP Ribose polymerase (PARP) inhibitors have led to an upsurge of …

5527 Background: Inactivating alts in BRCA1/2 result in homologous recombination
deficiency and are predictive of PARPi response in mCRPC. BRCA reversion mutations …

Prostate cancer is the second most frequent malignancy in men worldwide. Despite the
improvement in survival achieved by increasingly early diagnosis and advances in …

170 Background: Male BRCA mutation carriers have a 2-8-fold increased risk of prostate
cancer when compared to the general population, and up to 3% of patients (pts) with …